Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats

Behavioural Pharmacology

Volumn 25, Issue 2, 2014, Pages 119-129

  Kwilasz, Andrew J ^a,b   Abdullah, Rehab A ^a   Poklis, Justin L ^a   Lichtman, Aron H ^a   Negus, Sidney S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

antinociception; cannabinoid; FAAH inhibitor; intracranial self stimulation; pain; rat; stretching; URB597; writhing

Indexed keywords

ANALGESIC AGENT; ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; LACTIC ACID; AMIDASE; AMIDE; ARACHIDONIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; CANNABINOID RECEPTOR; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY-ACID AMIDE HYDROLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DEPRESSION; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; PAIN; RAT; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SELF ADMINISTRATION; ELECTROSTIMULATION; IMPLANTABLE NEUROSTIMULATOR; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

AMIDOHYDROLASES; ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; BENZAMIDES; BRAIN; CARBAMATES; CONDITIONING, OPERANT; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ENDOCANNABINOIDS; ENZYME INHIBITORS; IMPLANTABLE NEUROSTIMULATORS; INJECTIONS, INTRAPERITONEAL; LACTIC ACID; MALE; PAIN; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; SELF ADMINISTRATION;

EID: 84896401319     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000023     Document Type: Article

References (47)

1. Alvarez-Jaimes LJ, Palmer JA (2011). The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation. Curr Pharm Biotechnol 12:1644-1659.
2. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, et al. (2007). Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62: 1103-1110.
3. Bosier B, Muccioli GG, Lambert DM (2012). The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB(1) and FAAH-independent mechanisms. Br J Pharmacol 169:794-807.
4. Carlezon WA Jr, Chartoff EH (2007). Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2:2987-2995.
5. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, et al. (2006). Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148:102-113.
6. Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, et al. (2010). Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 13:1265-1270.
7. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87.
8. Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, Lichtman AH (2004). Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci USA 101:10821-10826.
9. De Vry J, Jentzsch KR, Kuhl E, Eckel G (2004). Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15:1-12.
10. Do Carmo GP, Folk JE, Rice KC, Chartoff E, Carlezon WA Jr, Negus SS (2009). The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats. Eur J Pharmacol 604:58-65.
11. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313:352-358.
12. Finn DP, Beckett SR, Roe CH, Madjd A, Fone KC, Kendall DA, et al. (2004). Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci 19:678-686.
13. Fowler CJ (2007). The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br J Pharmacol 152:594-601.
14. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. (2005). Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102:18620-18625.
15. Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM, et al. (1999). Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377:117-125.
16. Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG (2013). Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res 67:94-109.
17. Hasanein P, Parviz M, Keshavarz M, Roohbakhsh A (2009). URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats. Can J Physiol Pharmacol 87:432-439.
18. Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A (2004). Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308:446-453.
19. Huggins JP, Smart TS, Langman S, Taylor L, Young T (2012). An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabi-noids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153:1837-1846.
20. Jarbe TU, Gifford RS, Makriyannis A (2010). Antagonism of (9)-THC induced behavioral effects by rimonabant: time course studies in rats. Eur J Pharmacol 648:133-138.
21. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147:281-288.
22. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V (2006). Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26:13318-13327.
23. Karst M, Wippermann S, Ahrens J (2010). Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 70:2409-2438.
24. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81.
25. Kraft B (2012). Is there any clinically relevant cannabinoid-induced analgesia? Pharmacology 89:237-246.
26. Kwilasz AJ, Negus SS (2012). Dissociable effects of the cannabinoid receptor agonists {Delta}9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats. J Pharmacol Exp Ther 343:389-400.
27. Lizanecz E, Bagi Z, Pasztor ET, Papp Z, Edes I, Kedei N, et al. (2006). Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1. Mol Pharmacol 69:1015-1023.
28. Long JZ, LaCava M, Jin X, Cravatt BF (2011). An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase. J Lipid Res 52:337-344.
29. Miller LL, Picker MJ, Umberger MD, Schmidt KT, Dykstra LA (2012). Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice. J Pharmacol Exp Ther 342:177-187.
30. Naidu PS, Booker L, Cravatt BF, Lichtman AH (2009). Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 329:48-56.
31. National Research Council (2011). Guide for the care and use of laboratory animals. Washington DC: The National Academies Press.
32. Negus SS, Vanderah TW, Brandt MR, Bilsky EJ, Becerra L, Borsook D (2006). Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. J Pharmacol Exp Ther 319:507-514.
33. Negus SS, Bilsky EJ, Do Carmo GP, Stevenson GW (2010a). Rationale and methods for assessment of pain-depressed behavior in preclinical assays of pain and analgesia. Methods Mol Biol 617:79-91.
34. Negus SS, Morrissey EM, Rosenberg M, Cheng K, Rice KC (2010b). Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology (Berl) 210:149-159.
35. Negus SS, Rosenberg MB, Altarifi AA, O'Connell RH, Folk JE, Rice KC (2012). Effects of the delta opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats. J pain 13:317-327.
36. Negus SS (2013). Expression and treatment of pain-related behavioral depression. Lab Anim (NY) 42:292-300.
37. Pereira Do Carmo G, Stevenson GW, Carlezon WA, Negus SS (2009). Effects of pain-and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior. Pain 144:170-177.
38. Rice A (2006). Wall and Melzack's textbook of pain. Philadelphia: Churchill Livingstone.
39. Rosenberg MB, Carroll FI, Negus SS (2013). Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats. J pain 14:246-259.
40. Ross RA (2003). Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140:790-801.
41. Sagar DR, Kendall DA, Chapman V (2008). Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol 155:1297-1306.
42. Saghatelian A, McKinney MK, Bandell M, Patapoutian A, Cravatt BF (2006). A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 45:9007-9015.
43. Schlosburg JE, Kinsey SG, Lichtman AH (2009). Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J 11:39-44.
44. Tang L, Chen Y, Chen Z, Blumberg PM, Kozikowski AP, Wang ZJ (2007). Antinociceptive pharmacology of N-(4-chlorobenzyl)-N-(4-hydroxy-3-iodo-5- methoxybenzyl) thiourea, a high-affinity competitive antagonist of the transient receptor potential vanilloid 1 receptor. J Pharmacol Exp Ther 321:791-798.
45. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH (1998). Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285:285-292.
46. Xie S, Borazjani A, Hatfield MJ, Edwards CC, Potter PM, Ross MK (2010). Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carbox-ylesterases 1 and 2. Chem Res Toxicol 23:1890-1904.
47. Zhang D, Saraf A, Kolasa T, Bhatia P, Zheng GZ, Patel M, et al. (2007). Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology 52:1095-1105.